Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Genfit S.A. (GNFT.PA)
FR PAR Healthcare Biotechnology
Address
Parc EurasantE 59120
Loos, FR
Loos, FR
CEO
Pascal Prigent
Website
genfit.com
IPO
2006-12-19
ISIN FR0004163111
Also trades on
Euronext Paris · GNFT.PA (EUR)
NASDAQ Global Select · GNFT (USD)
Other OTC · GNFTF (USD)
Other OTC · GNFTY (USD)
Description
Genfit S.A. operates as a biopharmaceutical enterprise, concentrating its efforts on discovering and developing both therapeutic candidates and diagnostic solutions for metabolic and liver-related ailments. Its current pipeline includes Elafibranor, which is progressing through Phase 3 clinical trials for the treatment of primary biliary cholangitis (PBC). The firm is additionally engaged in advancing the NIS4 technology, designed for the accurate diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Other investigational treatments comprise GNS561, currently in Phase 1b/2 trials for cholangiocarcinoma (CCA), and Nitazoxanide, undergoing Phase 1 evaluation for acute-on-chronic liver failure. Genfit has established key partnerships, notably a licensing agreement with Labcorp for the commercialization of NASHnext, a molecular diagnostic test leveraging blood samples. Furthermore, it collaborates with Genoscience Pharma on the development and market launch of the experimental CCA therapy, GNS561. Established in 1999, Genfit S.A. maintains its headquarters in Loos, France.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
286.6K
Beta
1.12
Float Shares
44.12M
Free Float %
88.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.92% | +2.44% | +8.91% | -2.11% | +97.31% | +66.98% | +118.91% | +125.93% | +166.67% | -67.88% | -51.17% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (7 ratings, all time)
Buy
Price Targets & DCF
Current price
8.80
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-2.40
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-2.3% Q4'25: +123.9% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-5,833.3% Q4'25: -850.0% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-46.0% Q4'25: +14.6% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-90.1% Q4'25: -178.2% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-227.1% Q4'25: -838.4% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-0.8% ★ Q4'25: +0.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-18.74× Q4'25: -5.37× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 6 Rev. Ana. 2 EPS Ana. |
Dec 2028 5 Rev. Ana. 2 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
527.0K
est: 6.31M (-91.6%)
|
284.0K
est: 1.43M (-80.1%)
|
118.0K
est: 7.69M (-98.5%)
|
69.0K
est: 7.91M (-99.1%)
|
30.84M
est: 20.77M (+48.5%)
|
765.0K
est: 7.31M (-89.5%)
|
80.07M
est: 53.62M (+49.3%)
|
20.20M
est: 17.54M (+15.2%)
|
28.57M
est: 80.47M (-64.5%)
|
67.00M
est: 80.47M (-16.7%)
|
65.43M
est: 84.88M (-22.9%)
|
85.32M
85.11M – 85.53M
+0.5% YoY
|
112.75M
67.67M – 189.82M
+32.2% YoY
|
100.65M
100.55M – 100.75M
-10.7% YoY
|
180.39M
139.75M – 249.71M
+79.2% YoY
|
83.50M
64.69M – 115.59M
-53.7% YoY
|
| EBITDA |
-17.35M
est: -2.22M (-683.0%)
|
-33.53M
est: -501.0K (-6,592.7%)
|
-55.76M
est: -2.70M (-1,963.7%)
|
-68.08M
est: -2.78M (-2,351.3%)
|
-49.03M
est: -7.29M (-572.3%)
|
-73.03M
est: -2.57M (-2,745.2%)
|
71.89M
est: -18.83M (+481.8%)
|
-23.60M
est: -6.16M (-283.2%)
|
-22.24M
est: -14.14M (-57.2%)
|
8.35M
est: -14.14M (+159.0%)
|
-8.04M
est: -14.92M (+46.1%)
|
-15.00M
-15.03M – -14.96M
-0.5% YoY
|
-19.82M
-33.37M – -11.89M
-32.2% YoY
|
-17.69M
-17.71M – -17.67M
+10.7% YoY
|
-31.71M
-43.89M – -24.56M
-79.2% YoY
|
-14.68M
-20.32M – -11.37M
+53.7% YoY
|
| EBIT |
-17.68M
est: -2.36M (-647.6%)
|
-34.16M
est: -534.6K (-6,289.5%)
|
-56.69M
est: -2.88M (-1,866.1%)
|
-69.53M
est: -2.96M (-2,246.0%)
|
-54.28M
est: -7.78M (-597.5%)
|
-95.88M
est: -2.74M (-3,400.7%)
|
69.15M
est: -20.10M (+444.1%)
|
-25.44M
est: -6.57M (-287.0%)
|
-23.89M
est: -28.56M (+16.3%)
|
6.62M
est: -28.56M (+123.2%)
|
-58.92M
est: -30.12M (-95.6%)
|
-30.28M
-30.35M – -30.20M
-0.5% YoY
|
-40.01M
-67.36M – -24.01M
-32.2% YoY
|
-35.72M
-35.75M – -35.68M
+10.7% YoY
|
-64.01M
-88.61M – -49.59M
-79.2% YoY
|
-29.63M
-41.02M – -22.96M
+53.7% YoY
|
| Net Income |
-17.14M
est: -41.44M (+58.7%)
|
-33.67M
est: -66.36M (+49.3%)
|
-58.60M
est: -67.93M (+13.7%)
|
-79.52M
est: -104.00M (+23.5%)
|
-65.15M
est: -125.91M (+48.3%)
|
-101.22M
est: -108.11M (+6.4%)
|
67.26M
est: -76.08M (+188.4%)
|
-23.72M
est: -34.17M (+30.6%)
|
-28.89M
est: 22.27M (-229.7%)
|
1.51M
est: 17.04M (-91.2%)
|
-85.97M
est: -6.90M (-1,145.8%)
|
15.38M
12.82M – 17.95M
+322.9% YoY
|
57.96M
6.02M – 109.90M
+276.7% YoY
|
26.67M
26.41M – 26.92M
-54.0% YoY
|
140.47M
99.34M – 210.65M
+426.8% YoY
|
-8.47M
-12.71M – -5.99M
-106.0% YoY
|
| SGA |
9.13M
est: 44.14M (-79.3%)
|
11.66M
est: 9.98M (+16.8%)
|
13.41M
est: 53.82M (-75.1%)
|
4.50M
est: 55.32M (-91.9%)
|
30.97M
est: 145.28M (-78.7%)
|
25.49M
est: 51.13M (-50.2%)
|
17.69M
est: 375.13M (-95.3%)
|
17.40M
est: 122.68M (-85.8%)
|
8.04M
est: 31.88M (-74.8%)
|
20.13M
est: 31.88M (-36.8%)
|
20.69M
est: 33.62M (-38.5%)
|
33.80M
33.72M – 33.88M
+0.5% YoY
|
44.66M
26.80M – 75.19M
+32.2% YoY
|
39.87M
39.83M – 39.91M
-10.7% YoY
|
71.45M
55.36M – 98.91M
+79.2% YoY
|
33.08M
25.62M – 45.79M
-53.7% YoY
|
| EPS |
-0.69
est: -0.83 (+16.4%)
|
-1.28
est: -1.32 (+3.1%)
|
-1.88
est: -1.35 (-39.0%)
|
-2.55
est: -2.07 (-23.2%)
|
-1.76
est: -2.51 (+29.8%)
|
-2.60
est: -2.15 (-20.8%)
|
1.51
est: -1.51 (+199.7%)
|
-0.48
est: -0.89 (+46.2%)
|
-0.58
est: 0.45 (-229.4%)
|
0.03
est: 0.31 (-90.3%)
|
-1.72
est: -0.12 (-1,284.9%)
|
0.31
0.26 – 0.36
+348.5% YoY
|
0.83
0.12 – 2.20
+170.5% YoY
|
0.53
0.53 – 0.54
-35.9% YoY
|
2.82
1.99 – 4.23
+426.8% YoY
|
-0.17
-0.25 – -0.12
-106.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
14.77M
OE per share TTM
0.28
Owner's Yield
3.37%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
23.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 2 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Responsible International Equity ETF AVSD | 0.00% | 7.0K | 0.23% |
| 2 | Avantis International Small Cap Equity ETF AVDS | 0.00% | 4.1K | 0.30% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-327.3K
Shares Outstanding
50.08M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sakina Sayah-Jeanne | Chief Scientific Officer | 710.7K | female |
| Pascal Prigent | Chief Executive Officer | 646.9K | male |
| Jean-Francois Mouney | Co-Founder & Chairman of the Board | 410.7K | male |
| John Brozek | Executive VP of Data & Information Technology and Director | — | male |
| Laurent Lannoo | Corporate Secretary & Director of Legal Affairs | — | male |
| Pascal Caisey | Deputy CEO & COO | — | male |
| Pejvack Motlagh | Chief Medical Officer | — | — |
| Stefanie Magner | Chief Compliance Officer & Executive Vice President of International Legal Affairs | — | female |
| Thomas Baetz | Chief Financial Officer | — | male |
| Bart Staels | Co-Founder & Chairman of the Scientific Advisory Board | — | — |
| Tom Huijbers | Executive Vice President of Regulatory | — | male |
| Emilie Desodt | Executive Vice President of Human Resources | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GNFT.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
